Physician profile
Amit Mohan
NPI 1821219841
$236,190.71
in general payments reported to CMS, 2019-2025
31 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $43K · 2021: $48K · 2022: $3,276 · 2023: $672 · 2024: $1,498 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Travel and Lodging: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.44 |
| Travel and Lodging | $1,035.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $140,996.29 | 2019-2024 | Lybalvi, Aristada |
| Allergan, INC. | $45,166.83 | 2019-2021 | |
| Abbvie INC. | $22,173.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $22,162.20 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,665.45 | 2019-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $759.26 | 2020-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $689.65 | 2019-2020 | |
| Lundbeck LLC | $399.07 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $341.02 | 2019-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $336.92 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $312.70 | 2019-2023 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $224.36 | 2019-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $192.45 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $122.13 | 2019-2023 | Ingrezza |
| Neos Therapeutics, LP | $107.86 | 2019-2025 | Adzenys Xr-Odt |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $90.09 | 2019-2024 | |
| Harmony Biosciences LLC | $61.15 | 2022 | |
| Bausch Health US, LLC | $59.42 | 2020-2024 | Aplenzin |
| Indivior INC. | $54.64 | 2019-2020 | |
| Corium, LLC | $45.64 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $43.57 | 2020-2022 | |
| Adlon Therapeutics L.P. | $35.51 | 2019-2020 | |
| Tempus Ai, INC | $31.83 | 2024 | |
| Tris Pharma INC | $20.46 | 2022 | |
| Noven Therapeutics, LLC | $20.23 | 2023 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $18.00 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $17.00 | 2024 | Quviviq |
| Sun Pharmaceutical Industries INC. | $14.28 | 2020 | |
| Neuronetics, INC. | $13.80 | 2023 | Neurostar Tms Therapy System |
| Arbor Pharmaceuticals, INC. | $13.33 | 2019 | |
| Validus Pharmaceuticals LLC | $2.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.